The last 20 years of respiratory medical practice have seen many changes. As other subspecialties such as oncology, infectious diseases, allergy/immunology, intensive care, and occupational medicine increasingly make inroads into the traditional areas of respiratory practice, new fields requiring the expertise of the respiratory physician have developed. Arguably the dominant examples of these are disorders of breathing in sleep. Until recently terms such as "REM sleep," "apnoea index," and "nasal CPAP" were foreign to most people working in respiratory medicine. The parallel development of methods of measuring ventilation and blood gas levels non-invasively with the standardised monitoring of sleep has led to a recognition that sleep disorders-particularly abnormal breathing during sleep-are both causes and contributors to a broad spectrum of clinical morbidity and mortality.
While researchers and clinicans working in the field agree on the importance of accurate diagnosis and appropriate treatment for patients with sleep breathing disorders, there is considerable disparity in the availability of investigation and treatment for such patients in different countries. In the USA it has been estimated that there is more than one sleep laboratory per 250 000 people; in Australia there is at least one per 1 000 000, but in the UK the ratio is much lower. While these differences in the availability of facilities may reflect a variation in health care expenditure or structure, it is likely that they also reflect a divergence in the relative importance with which health planners and policy makers view disorders of breathing in sleep. To provide a detailed review of recent advances in the understanding of sleep and breathing disorders requires a monograph.' The purpose of this review is to assess some recent developments in the most common sleep breathing disorder-obstructive sleep apnoea-with particular emphasis on recent data on diagnosis, prevalence, predisposing factors, clinical sequelae, and treatment in the adult patient.
Diagnosis and prevalence
WHAT IS OBSTRUCTIVE SLEEP APNOEA?
One of the key problems in recognising the importance of obstructive sleep apnoea (OSA) is the lack of a clearly agreed definition. While an apnoea is agreed upon as a cessation of breathing for 10 or more seconds,2 there is a wide range in the frequency of such events during sleep; how this frequency (or "respiratory disturbance index") correlates with disease severity and incidence continues to be debated.3 Most researchers use a working definition of five apnoeas per hour to define sleep disordered breathing2 but this is by no means consistent in the literature. This definition was developed at a time when OSA was thought to be a rare disorder and these arbitrary cut offs allowed researchers to communicate in a common "language"-an important consideration in reviewing any literature on this subject. As OSA is increasingly recognised as a common disorder such definitions need to be reconsidered.
Most clinicians recognise OSA as a disorder characterised by repetitive apnoeas, loud snoring, and excessive daytime sleepiness. However, in OSA the patient is often the last to realise the extent of the mental and physical effects of the disorder. Recent studies have shown that some forms of OSA may occur without the presence of snoring4 or apnoea5 but with obvious clinical effects. Similarly, excessive daytime sleepiness may not occur but instead the clinical picture may mimic an anxiety state, especially in women.6
Adult criteria for OSA may also not be appropriate in children. The cardiovascular consequences of OSA can be considered from two aspects. Firstly, the acute cardiovascular changes that occur during an apnoea with the associated hypoxia, hypercapnia, acidosis, and arousal from sleep, and secondly, the chronic cardiovascular morbidity and mortality associated with OSA, namely hypertension, myocardial infarction, stroke, and death.
Acute effects
Obstructive apnoeas are accompanied by profound haemodynamic changes.71 Cyclical increases in systemic and pulmonary arterial blood pressure occur coincidently with obstructive events.72 Each apnoea can be considered in three phases with respect to the observed effects on blood pressure, heart rate, sympathetic and parasympathetic nerve activity, and cardiac output.71 Phase 1 (recovery from the previous apnoea typically during the early part of the next apnoea) is characterised by minor pleural pressure swings, minimal changes in heart rate and muscle sympathetic nerve activity (MSNA), and modest changes in oxygen saturation. As the apnoea progresses (phase 2) there is progressive hypoxaemia, increasing pleural pressure swings, bradycardia (and possibly bradyarrhythmias), heightened MSNA, and an overall rise in blood pressure. With arousal and resumption of ventilation (phase 3) oxygen saturation returns to normal. There are significant increases in heart rate and blood pressure may rise to levels ranging from 200 to 300 mm Hg. In phase 3 MSNA increases, but this appears to be rapidly interrupted before the peak in blood pressure following apnoea. There is a fall in stroke volume during apnoea, particularly at its termination.7 '74 The combination of fall in stroke volume and rise in blood pressure suggests a substantial increase in total peripheral resistance.
The potentiation of MSNA activity during apnoea is likely to be the result of a combination of apnoea and hypoxaemia. Somers sure. In addition, changes in intracranial pressure may influence blood pressure. 88 Other evidence for a potential effect of OSA on development of hypertension has been provided by an elegant series of studies in rats exposed to seven weeks of intermittent hypoxia.89-9' These animals developed persistent elevation of daytime mean arterial pressure. Sectioning of the carotid sinus nerve and chemical peripheral sympathectomy with 6-hydroxydopamine eliminated the persistent elevation of blood pressure. 90 9' Increased left ventricular wall thickening, independent of resting daytime blood pressure, has been observed in OSA. 92 105 Naughton and Pierce reported a fall in automated daytime blood pressure readings in hypertensive patients with OSA after one week of CPAP. 106 However, some of these patients were also receiving antihypertensive drugs. In a study of 24 hour ambulatory blood pressure in 19 men with OSA before and after eight weeks (fig 4) . This fall occurred in the 14 patients with good CPAP compliance but not in those unable to use CPAP. This is the first study to report a decrease in ambulatory daytime blood pressure following treatment of OSA. Such a daytime fall may not be unexpected in view of the high sympathetic nerve traffic during wakefulness observed in untreated patients with OSA7880 and the decrease in sympathetic activity seen following nasal CPAP treatment.71 Recent preliminary data have also suggested that patients with OSA may have abnormally high responses to daytime stressors such as mental arithmetic which are reversible with treatment (JH Peter, personal communication). One criticism of this 24 hour ambulatory blood pressure study is the lack of a placebo treated control group to avoid "regression to the mean." This phenomenon has not, however, been observed in 24 hour ambulatory blood pressure studies'08 and "placebo" CPAP has not been successfully used in any short or long term study. Such a technique would be obvious to the patient and bed partner as snoring and upper airway obstruction would continue and the expected improvement in daytime sleepiness with CPAP treatment would not occur. The "Pickwickian" patients described in older literature were often characterised by marked obesity, right heart failure, and awake respiratory failure with hypercapnia."17 They clearly represent the severe end of the spectrum of OSA, and it is evident that upper airway obstruction during sleep in the presence of other factors will produce the "Pickwickian" patient. What are the factors that will transform a patient with OSA into a "Pickwickian" patient? Firstly, there is likely to be a complex interrelationship between these factors. Some patients develop hypercapnia without evidence of right heart failure and the reverse is also true. Most studies examining this interrelationship are limited in size and vary in the method of assessing right heart failure. The key factors suggested are presence of chronic airflow limitation, obesity, awake hypoxaemia, hypercapnia, profound nocturnal hypoxaemia, and alcohol consumption."'1122 A recent preliminary report has shown that daytime Pco2 and FEV1 explain 29% of the variability in pulmonary artery pressure in sleep apnoea. Daytime hypoxaemia had no independent contribution. Of 78 patients with pulmonary hypertension and FEV, >1-51, 30% had a Po2 >80 mmHg. These data suggest that patients with OSA can often develop pulmonary hypertension in the absence of daytime hypoxaemia.12' Treatment of "Pickwickian" patients and other patients with OSA and pulmonary hypertension leads to a normalisation of both hypercapnia and pulmonary artery pressure. 120 found. -35-139 Moreover, the response to surgery is highly variable. Most papers define a "cure" as a 50% reduction in the number of apnoeas per hour of sleep; in many patients with repetitive apnoea, however, these "cures" will still leave a substantial degree of sleep disordered breathing. Results are frequently reported without detailed examination of sleep quality, hypopnoea, or arousals. Polo et al,141 while observing a decrease in obstructive apnoea following UPPP, found an increase in partial upper airway obstruction thus stressing the importance of close postoperative follow up. This may also explain why investigators reporting apnoea reduction following UPPP find no correlation between subjective and objective improvement."5
One of the problems in examining the long term efficacy of UPPP is that most papers report short term results or have incomplete follow up. Recently Larsson et al36 reported a two year follow up of 50 consecutive patients who underwent UPPP. After six weeks 60% of patients were classified as "responders" (50% decrease in apnoea index or number of apnoeas per hour). At two years the "response rate" had fallen to 36%. In addition there are data"35 137-138 suggesting an appreciable morbidity and mortality for patients treated by UPPP, while the increased mortality of OSA is not modified by UPPP. 109 There is also some evidence that the vibration of snoring may protect against further upper airway obstruction,'42 suggesting that removal of the vibrating tissues (plate, uvula) may critically alter important upper airway afferent receptors, thereby causing narrowing and airway closure during sleep at other sites postoperatively.
Recently a novel technique using nasopharyngoscopy during sleep, simultaneous use of nasal CPAP to manipulate intrapharyngeal pressure, and digitised computer assessment of airway lumen size has been employed to select patients who may respond to UPPP. 140 The authors could identify patients with exclusively nasopharyngeal narrowing of the passive airway. Such patients had 50% improvement in severity of sleep apnoea four months after UPPP compared with no change in the non-exclusively nasopharyngeal occluders. There was, however, a deterioration in the severity of OSA at 14 month follow up. Moreover, "responders" still had a substantial degree of disordered breathing in sleep at 14 months after surgery (mean apnoea index 58, with 35% of total sleep time spent in disordered breathing). Such pre-UPPP assessment techniques are complex and expensive and current results do not seem to warrant more widespread use. It is possible that better results may be produced in patients with milder OSA. It is therefore important to stress that UPPP remains an experimental treatment method in OSA. Careful objective preoperative and postoperative assessment of breathing during sleep with long term follow up should be performed.
Conclusion
Obstructive sleep apnoea is a common disorder which will become an increasingly important part of respiratory practice. The best methods of diagnosis are costly and increased sophistication of screening devices and interpreting physicians are required to reduce the need for full polysomnography. There is a wide range of clinical disorders associated with OSA which affect the decision to treat patients. However, in some cases the link between OSA and these clinical disorders has not been proved convincingly. Studies clarifying these issues will allow better selection of patients requiring treatment. Nasal CPAP is the standard treatment for OSA and tracheostomy should only be considered in patients truly unable to tolerate CPAP. Uvulatopalatopharyngoplasty and facial reconstructive surgery should only be considered as part of objective controlled trials.
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